Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873192 | 0.87 | ALDH1A1 (0.51) | MAPTMEN1KMT2AMRGPRX4ALDH1A1 | |
| SCHEMBL4877619 | 0.84 | NPC1 (0.41) | MAPTMRGPRX4ALDH1A1NPC1RAB9A | |
| SCHEMBL2528357 | 0.84 | NPC1 (0.42) | MAPTMRGPRX4ALDH1A1NPC1RAB9A | |
| SCHEMBL2528507 | 0.80 | NPC1 (0.40) | MAPTALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL644117 | 0.79 | MAPT (0.44) | MAPTALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL20395893 | 0.79 | MAPT (0.44) | MAPTALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL4878536 | 0.79 | KDM4E (0.39) | MAPTALDH1A1NPC1RAB9AKDM4E | |
| Hydrogen Sulfide SCHEMBL20395882 | 0.78 | MAPT (0.43) | MAPTALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL15780544 | 0.78 | CNR1 (0.47) | MAPTALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL642424 | 0.77 | CA12 (0.56) | MAPTALDH1A1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | MAPT 37/4885MEN1 306/4885CYP3A4 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.